Physician profile
Christopher Jackson Davis
NPI 1144473208
$226,097.87
in general payments reported to CMS, 2019-2025
12 companies · $154 in 2025
The $154 reported for 2025 was more than what a typical Addiction Medicine (Internal Medicine) provider received nationally (typical 2025 total: $124).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98K · 2020: $29K · 2021: $45K · 2022: $17K · 2023: $21K · 2024: $16K · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Travel and Lodging: $3,302 · Food and Beverage: $1,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,670.00 |
| Travel and Lodging | $3,301.55 |
| Food and Beverage | $1,400.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $225,741.17 | 2019-2024 | Vivitrol, Vivitrol, Aristada |
| Gilead Sciences, INC. | $74.55 | 2020 | |
| Corium, LLC | $63.19 | 2023-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53.11 | 2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $40.90 | 2025 | |
| Braeburn INC. | $27.84 | 2025 | Brixadi |
| Abbott Laboratories | $23.29 | 2024 | Octrode |
| Medtronic, INC. | $16.00 | 2025 | Intellis Adaptivestim |
| Ardelyx, INC. | $15.90 | 2023 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.04 | 2019 | |
| Amgen INC. | $13.79 | 2024 | Prolia, Evenity |
| Merck Sharp & Dohme LLC | $13.09 | 2024 | Vaxelis, Vaxneuvance, Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.